Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.817,67
0,14%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PDS Biotechnology Corporation (PDSB) PDS Biotechnology Corporation (PDSB) Notizie

PDSB

PDS Biotechnology (PDSB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PDSB
DataOraFonteTitoloSimboloCompagnia
15/05/202423:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PDSBPDS Biotechnology Corporation
15/05/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
23/01/202422:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PDSBPDS Biotechnology Corporation
23/01/202422:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PDSBPDS Biotechnology Corporation
22/01/202422:45GlobeNewswire Inc.PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical OfficerNASDAQ:PDSBPDS Biotechnology Corporation
16/01/202414:00GlobeNewswire Inc.PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
04/12/202322:50GlobeNewswire Inc.PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PDSBPDS Biotechnology Corporation
28/11/202313:30GlobeNewswire Inc.PDS Biotech Appoints Lars Boesgaard as Chief Financial OfficerNASDAQ:PDSBPDS Biotechnology Corporation
14/11/202313:30GlobeNewswire Inc.PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PDSBPDS Biotechnology Corporation
09/11/202314:00GlobeNewswire Inc.PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 MonthsNASDAQ:PDSBPDS Biotechnology Corporation
07/11/202314:00GlobeNewswire Inc.PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial ResultsNASDAQ:PDSBPDS Biotechnology Corporation
23/10/202314:00GlobeNewswire Inc.PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMONASDAQ:PDSBPDS Biotechnology Corporation
11/10/202314:00GlobeNewswire Inc.PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate CancerNASDAQ:PDSBPDS Biotechnology Corporation
03/10/202313:00GlobeNewswire Inc.PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:PDSBPDS Biotechnology Corporation
02/10/202314:00GlobeNewswire Inc.PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)NASDAQ:PDSBPDS Biotechnology Corporation
26/09/202314:00GlobeNewswire Inc.PDS Biotech to Present at the LD Micro Main Event XVINASDAQ:PDSBPDS Biotechnology Corporation
25/09/202314:00GlobeNewswire Inc.PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101NASDAQ:PDSBPDS Biotechnology Corporation
20/09/202322:05GlobeNewswire Inc.PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
20/09/202314:00GlobeNewswire Inc.PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical StudiesNASDAQ:PDSBPDS Biotechnology Corporation
13/09/202314:00GlobeNewswire Inc.PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023NASDAQ:PDSBPDS Biotechnology Corporation
06/09/202322:05GlobeNewswire Inc.PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
06/09/202314:00GlobeNewswire Inc.PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
16/08/202314:00GlobeNewswire Inc.PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual MeetingNASDAQ:PDSBPDS Biotechnology Corporation
14/08/202313:30GlobeNewswire Inc.PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PDSBPDS Biotechnology Corporation
14/08/202313:00GlobeNewswire Inc.PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 TrialNASDAQ:PDSBPDS Biotechnology Corporation
07/08/202314:00GlobeNewswire Inc.PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial ResultsNASDAQ:PDSBPDS Biotechnology Corporation
02/08/202314:00GlobeNewswire Inc.PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023NASDAQ:PDSBPDS Biotechnology Corporation
25/07/202314:00GlobeNewswire Inc.PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023NASDAQ:PDSBPDS Biotechnology Corporation
17/07/202314:00GlobeNewswire Inc.PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023NASDAQ:PDSBPDS Biotechnology Corporation
11/07/202314:00GlobeNewswire Inc.PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301NASDAQ:PDSBPDS Biotechnology Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PDSB

La tua Cronologia

USOTC
SECTF
SSGA SPDR ETFS Europe II (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network